Maher J - Search Results

1

Can Bile Salt Export Pump Inhibition Testing in Drug Discovery and Development Reduce Liver Injury Risk? An International Transporter Consortium Perspective.

Kenna JG, Taskar KS, Battista C, Bourdet DL, Brouwer KLR, Brouwer KR, Dai D, Funk C, Hafey MJ, Lai Y, Maher J, Pak YA, Pedersen JM, Polli JW, Rodrigues AD, Watkins PB, Yang K, Yucha RW; International Transporter Consortium. Kenna JG, et al. Among authors: maher j. Clin Pharmacol Ther. 2018 Nov;104(5):916-932. doi: 10.1002/cpt.1222. Clin Pharmacol Ther. 2018. PMID: 30137645 Free PMC article. Review.

2

Individual serum bile acid profiling in rats aids in human risk assessment of drug-induced liver injury due to BSEP inhibition.

Cepa S, Potter D, Wong L, Schutt L, Tarrant J, Pang J, Zhang X, Andaya R, Salphati L, Ran Y, An L, Morgan R, Maher J. Cepa S, et al. Among authors: maher j. Toxicol Appl Pharmacol. 2018 Jan 1;338:204-213. doi: 10.1016/j.taap.2017.11.007. Epub 2017 Nov 13. Toxicol Appl Pharmacol. 2018. PMID: 29146462

3

In vitro assessment of farnesoid X receptor antagonism to predict drug-induced liver injury risk.

Norona LM, Fullerton A, Lawson C, Leung L, Brumm J, Kiyota T, Maher J, Khojasteh C, Proctor WR. Norona LM, et al. Among authors: maher j. Arch Toxicol. 2020 Sep;94(9):3185-3200. doi: 10.1007/s00204-020-02804-4. Epub 2020 Jun 24. Arch Toxicol. 2020. PMID: 32583097

4

Establishment of baseline profiles of 50 bile acids in preclinical toxicity species: A comprehensive assessment of translational differences and study design considerations for biomarker development.

Sangaraju D, Katavolos P, Liang X, Chou C, Zabka TS, Dean B, Maher J. Sangaraju D, et al. Among authors: maher j. Toxicol Appl Pharmacol. 2022 May 15;443:116008. doi: 10.1016/j.taap.2022.116008. Epub 2022 Apr 1. Toxicol Appl Pharmacol. 2022. PMID: 35378153

5

Safety Lead Optimization and Candidate Identification: Integrating New Technologies into Decision-Making.

Dambach DM, Misner D, Brock M, Fullerton A, Proctor W, Maher J, Lee D, Ford K, Diaz D. Dambach DM, et al. Among authors: maher j. Chem Res Toxicol. 2016 Apr 18;29(4):452-72. doi: 10.1021/acs.chemrestox.5b00396. Epub 2015 Dec 16. Chem Res Toxicol. 2016. PMID: 26625186 Review.

6

Using Genetically Modified Rodent Models in Drug Development to Explore Target Physiology and Potential Drug Effects.

Zhong Y, Dambach DM, Maher JM. Zhong Y, et al. Vet Pathol. 2018 Mar;55(2):193-194. doi: 10.1177/0300985817747328. Vet Pathol. 2018. PMID: 29457566 No abstract available.

7

Lung-restricted ALK5 inhibition avoids systemic toxicities associated with TGFβ pathway inhibition.

Maher JM, Zhang R, Palanisamy G, Perkins K, Liu L, Brassil P, McNamara A, Lo A, Hughes AD, Kanodia J, Kulyk S, Nikula KJ, Dengler HS, Scandurra A, Lua I, Harstad E. Maher JM, et al. Toxicol Appl Pharmacol. 2022 Mar 1;438:115905. doi: 10.1016/j.taap.2022.115905. Epub 2022 Feb 3. Toxicol Appl Pharmacol. 2022. PMID: 35122773 Free article.

8

Predicting Human Infection Risk: Do Rodent Host Resistance Models Add Value?

Wu KC, Zhong Y, Maher J. Wu KC, et al. Among authors: maher j. Toxicol Sci. 2019 Aug 1;170(2):260-272. doi: 10.1093/toxsci/kfz116. Toxicol Sci. 2019. PMID: 31106824 Review.

9

Cardiovascular microphysiological systems (CVMPS) for safety studies - a pharma perspective.

Pointon A, Maher J, Davis M, Baker T, Cichocki J, Ramsden D, Hale C, Kolaja KL, Levesque P, Sura R, Stresser DM, Gintant G. Pointon A, et al. Among authors: maher j. Lab Chip. 2021 Feb 9;21(3):458-472. doi: 10.1039/d0lc01040e. Lab Chip. 2021. PMID: 33471007

10

[No title available]

[No authors listed] [No authors listed] PMID: 31962949

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

1,243 results

Search Page